

Autonomic Neuropathic Changes in Diabetes: Early marker of Impending Complications

Nimarpreet Kaur, Hatinder Jeet Singh Sethi, Dimple Bajaj

Assistant Professor, Physiology, SGT Medical College, Gurgaon

Consultant Internal Medicine, Medeor Hospital, Gurgaon, Professor SGRD Amritsar

Abstract

Background: Cardiac autonomic neuropathy (CAN) is a critical intricacy of diabetes mellitus. Autonomic neuropathy is postulated to be an indicator of impending demise. It is not very easy to detect the diabetic autonomic neuropathy at an earlier stage. The objective of this study was to weigh up the affiliation between autonomic neuropathy and the heart rate variability (HRV) in Type 2 Diabetics. HRV can indicate early subclinical manifestation of autonomic dysfunction, and this could be of value from clinical perspective to understand the risk associated with the subject and further management. In other words, having HRV insight may influence the aggressiveness of the intervention and the choice of therapy when dealing with hyperglycaemia and the complications and also for identifying potential risks, which are not obvious (e.g., CAN). **Methods:** The present study was conducted on 50 type 2 Diabetics attending the diabetic clinic and 25 healthy attendants served as controls. The patients were divided into two major groups, i.e. (<5 years of duration, >5 years of duration), Autonomic nervous system activity was evaluated. HRV was measured by Standing to lying ratio (S/L ratio), 30/15 ratio, Valsalva ratio and Deep breathing test (DBT). The results were statistically analysed. **Results:** Significant changes in parasympathetic activity (30:15 ratio, DBT, S/L ratio) were observed in diabetics as compared to normal which progressed with duration of disease (<5 years vs >5 years, $p < 0.05$). **Conclusion:** With early detection of autonomic neuropathy, use of aggressive approach in management of Diabetes Mellitus would reduce mortality and morbidity in these patients.

Keywords: Cardiac autonomic neuropathy (CAN), Diabetes Mellitus, Heart Rate Variability (HRV)

Date of Submission: 11-11-2019

Date of Acceptance: 27-11-2019

I. Introduction

According to WHO, Chronic diseases are defined as diseases of long duration and slow progression, precipitated by factors having close association with surroundings and lifestyle of a person.¹ Diabetes is a silent killer affecting all organs either directly or indirectly through various mechanisms which are mainly due to changes in blood glucose, free fatty acids and biochemical markers levels.² Stress, lifestyle, environment, genetic predisposition add on to the complications which include various microvascular and the macrovascular complications.^{3,4,5} Autonomic dysfunction is the most deadly complication leading on to organ dysfunction and cardiac autonomic neuropathy which leads to alteration in the rhythm of heart involving parasympathetic system initially then sympathetic system.⁶⁻⁹

Cardiovascular autonomic neuropathy is defined as the impairment of autonomic control of the cardiovascular system¹⁰. Subclinically, the disease is defined by cardiovascular reflex testing, which may have prognostic implications. Clinically, the impairment in autonomic function is associated with resting tachycardia, exercise intolerance, orthostatic hypotension, syncope, intraoperative cardiovascular instability, silent myocardial infarction and ischemia, and increased mortality¹¹. Autonomic neuropathies impinging cardiovascular system cause resting tachycardia and orthostatic hypotension. Reports of sudden death have also been ascribed to autonomic neuropathy.¹²

The evaluation of cardiovascular autonomic function is the cornerstone of the clinical investigation of autonomic function. The anatomic situation of the cardiovascular autonomic nervous system renders it inconvenient for simple direct physiological testing. Consequently, autonomic tests based on cardiovascular reflexes to various physiological agitations (e.g., heart rate response to deep breathing, postural change, and the Valsalva manoeuvre and blood pressure response to sustained hand grip and postural change) are usually employed.

II. Material And Methods

The study was conducted on 50 Type 2 diabetics which were further divided into two groups according to the duration of disease, less than 5 years of disease and more than 5 years of disease. Detailed history of the patients were taken and enquired about their lifestyle and the various battery of tests were done assessing their pulse rate, blood pressure and ECG with posture variations i.e. sympathetic and parasympathetic parameters were completely evaluated. ECG for autonomic function testing was done with RMS ECG machine, using standard limb lead-II. Blood pressure was recorded using sphygmomanometer. Sympathetic activity was measured by cold pressor test, hand grip test, and blood pressure response to standing. Parasympathetic activity was measured by S/L ratio, 30/15 ratio, valsalva ratio and I/E ratio.

Observations were recorded and interpreted. Data were analysed using SPSS-10. The statistical difference in mean values was tested using ANOVA with post hoc turkey, and $p < 0.05$ was taken as significant.

III. Results

TABLE 1

GROUP	DURATION OF DISEASE	NO.OF PATIENTS
NIDDM Ia	<5 years	25
NIDDM Ib	>5 years	25
CONTROL II		25

TABLE 2: Pre-test mean values of pulse rate and blood pressure in all the groups

Groups	No.	Pulserate (per min) (range)	Pulse rate Mean±SD	SBP (mm Hg)(range)	SBP Mean±SD	DBP (mm Hg)(range)	DBP Mean±SD
Ia	25	66-107	86.88±11.49	120-160	136.08±9.44	70-92	84.64±4.78
Ib	25	60-130	82.52±16.48	110-154	138.40±9.52	68-100	86.40±6.21
II	25	70-80	76.84±5.46	104-134	120.16±9.39	60-88	76.96±7.83

TABLE 3 Mean values of parasympathetic function tests

Data analysis showed that:

1. Out of 50 diabetics only 8 had active life style while 42 had sedentary mode of living adding on to the disease status.
2. Increase in mean pulse rate, Systolic blood pressure and diastolic blood pressure in the two groups. Increase in pulse rate is statistically significant $p < 0.05$ as compared to the control group and loss of variability of heart rate with duration of disease is seen. Pre test mean value for DBP is highly significant when compared between the two groups $p < 0.01$.
3. Sympathetic impairment evident by postural fall in BP, occurred in Group Ib and is statistically significant. But the cold pressor test and Hand grip test did not show significant change.

Group s	30:15 ratio Range Mean±SD		Valsalva ratio Range Mean±SD		DBT Range Mean±SD		S/L ratio Range Mean±SD	
	Ia	0.9-1.12	1.01±0.05	0.8-1.93	1.15±0.28	4-13	7.80±2.27	0.75-1.35
Ib	0.93-1.08	1.00±0.05	0.9-1.85	1.19±0.25	3-12	7.40±2.30	0.8-1.08	0.95±0.08
II	1.0-1.14	1.05±0.04	1.04-1.25	1.15±0.08	12-22	17.88±3.14	1-1.5	1.22±0.18

4. Parasympathetic parameters showed deterioration with the duration of the disease. The statistical comparison for 30:15 ratio, Valsalva ratio and Deep breathing were highly significant and progressed with the duration of the disease.

IV. Discussion

Autonomic neuropathy is a frequently observed intricacy of diabetes that has a noteworthy distressing influence on the survival and quality of life of the patients. Generally, diabetic autonomic neuropathy may be clinically evident long after the onset of diabetes. Sub-clinical autonomic dysfunctions can occur within a year

of Type 2 diabetes diagnosis. Early awareness of autonomic dysfunctions can encourage patients and physicians to improve metabolic control and use the treatments that may be effective in patients with autonomic dysfunctions, particularly cardiac autonomic dysfunction (CAN).¹³

Cardiac marker heart rate variability (HRV) is an eloquent, sensitive and early prognosticator which can be used for early diminution of complications among diabetics.¹⁴ It was observed that there is resting tachycardia in diabetics. These findings are consistent with the study done by Shuldiner *et al*¹⁵ in which the authors observed resting tachycardia in diabetics suffering from cardiovascular autonomic neuropathy. Similar were the observations of other authors.^{16,17} The involvement of the vagal parasympathetic component of autonomic nervous system is obvious in Diabetic patients. This is evidenced by increased resting heart rate and decreased Valsalva ratio; E/I index and standing ratio in diabetics relative to controls. These findings are in line with those of Freccero *et al*¹⁸ who reported a high frequency of parasympathetic and sympathetic neuropathy in both type 1 and type 2 diabetic patients. They suggested that severe damage to large myelinated nerve fibres in addition to the widespread neurological degeneration which usually affects the small nerve fibres of the autonomic nervous system was culpable for profound parasympathetic neuropathy in patients with T2DM.^{19,20}

Other researchers also found appreciable degree of autonomic neuropathy in patients with T2DM. In fact significantly reduced HRV measures in DM patients compared to controls have been previously verified in large-population-based studies.^{21,22} The same results had also been documented in the Framingham Heart Study and in the Atherosclerosis Risk in Communities (ARIC) cohort.^{22,23}

V. Conclusion

Autonomic signs and symptoms are common in diabetes and with early detection of autonomic neuropathy, use of aggressive approach in management of Diabetes Mellitus, would reduce mortality and morbidity in these patients.

Bibliography

- [1]. Trivedi GY, Saboo B, Singh RB, Maheshwari A, Sharma K, Verma N. Can decreased heart rate variability be a marker of autonomic dysfunction, metabolic syndrome and diabetes? *J Diabetol*(serial online) ; 10:48-56.
- [2]. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001;414:813-20.
- [3]. Brennan E, McEvoy C, Sadler D, Godson C, Martin F. The genetics of diabetic nephropathy. *Genes (Basel)* 2013;4:596-619.
- [4]. Wilson NM, Wright DE. Inflammatory Mediators in Diabetic Neuropathy. *J Diabetes Metab* 2011;S5004. Doi:10.4172/2155-6156.S5-004.
- [5]. Fowler M. Microvascular and macro vascular complications of diabetes. *Clin Diabetes* 2008;26:77-82.
- [6]. Vinik AI, Mehrabyan A. Diabetic neuropathies. *Med Clin North Am* 2004;88:947-99, xi.
- [7]. Ewing DJ, Borse DQ, Bellavere F, Clarke BF. Cardiac autonomic neuropathy in diabetes: Comparison of measures of R-R interval variation. *Diabetologia* 1981;21:18-24.
- [8]. Bellavere F, Balzani I, De Masi G, Carraro M, Carenza P, Cobelli C, *et al*. Power spectral analysis of heart-rate variations improves assessment of diabetic cardiac autonomic neuropathy. *Diabetes* 1992;41:633-40.
- [9]. Jelinek HF, Cree MJ. Automated Image Detection of Retinal Pathology. Boca Raton: CRC Press; 2009.
- [10]. Tesfaye S, Boulton AJ, Dyck PJ, *et al*. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care* 2010; 33:2285.
- [11]. Vinik AI, Erbas T. diabetic autonomic neuropathy. *Handb Clin Neurol* 2013; 117:279.
- [12]. Blessing B, Gibbins I. Autonomic nervous system. *Scholarpedia Australia* 2008;3(7):2787-9.
- [13]. Lafitte MJ, Genoulaz MF, Srikanta SS, Punitha L, Vidyanand S. 500 Heart beats for assessing diabetic autonomic neuropathy. *Int J Diabetes Dev Ctries* 2005;25:113-7.
- [14]. Raja JM, Mary A. Heart Rate Variability, a cardiac indicator in diabetic autonomic neuropathy: a systematic review. *Int J Med Res* 2013;1(2):13-6.
- [15]. Shuldiner AR, McLenithan JC. Genes and pathophysiology of type 2 diabetes: more than just the Randle cycle all over again. *J Clin Invest* 2004;114(10):1414-7.
- [16]. Barkai L, Madacsy L. Cardiovascular autonomic dysfunction in diabetes mellitus. *Arch Dis Child* 1995;73:515-8.

- [17]. Koharo H, Ansari S, Shaikh I, Qureshi F. Cardiac Autonomic Neuropathy (CAN) in type-1 diabetes mellitus patients and its association with the duration of disease and glycemic control. *J Coll Physicians Surg Pak* 2009;19(4):232–5.
- [18]. Freccero C, Svensson H, Bornmyr S, Wollmer P, Sundkvist G. Sympathetic and parasympathetic neuropathy are frequent in both type 1 and type 2 diabetic patients. *Diabetes Care* 2004;27(12):2936–41.
- [19]. Sucharita S, Bantwal G, Idiculla J, Ayyar V, Vaz M. Autonomic nervous system function in type 2 diabetes using conventional clinical autonomic tests, heart rate and blood pressure variability measures. *Indian J Endocrinol Metabol* 2011;15(3):198–203.
- [20]. Khatoon N, Kumar B, Hazari M. Cardiovascular autonomic neuropathy in patients with diabetes mellitus. *Int J Pharma Bio Sci* 2010;1(3):1–7.
- [21]. Gerritsen J, Dekker JM, TenVoorde BJ, Kostense PJ, Heine RJ, Bouter LM, *et al.* Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease. The Hoorn Study. *Diabetes Care* 2001;24(10):1793–8.
- [22]. Singh JP, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, *et al.* Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). *Am J Cardiol* 2000;86(3):309–12.
- [23]. Liao D, Cai J, Brancati FL, Folsom A, Barnes RW, Tyroler HA, *et al.* Association of vagal tone with serum insulin, glucose, and diabetes mellitus—The ARIC study. *Diabetes Res ClinPract* 1995;30(3):211–21.

Nimarpreet Kaur. "Autonomic Neuropathic Changes in Diabetes: Early marker of Impending Complications." *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, vol. 18, no. 11, 2019, pp 15-18.